Stockreport

MEDIA STATEMENT - Novartis Canada disappointed with outcome of pCPA negotiations for metastatic castration resistant prostate cancer treatment PLUVICTO™ [Yahoo! Finance]

Novartis AG  (NVS) 
Last novartis ag earnings: 4/28 01:00 am Check Earnings Report
US:NYSE Investor Relations: novartis.com/investors
PDF PLUVICTO™ (lutetium (177Lu) vipivotide tetraxetan injection), a treatment for patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mC [Read more]